Subchronic arsenic exposure induces anxiety-like behaviors in normal mice and enhances depression-like behaviors in the chemically induced mouse model of depression

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Chang, Chia Yu ^a,b   Guo, How Ran ^c,d,e   Tsai, Wan Chen ^b   Yang, Kai Lin ^b   Lin, Li Chuan ^b   Cheng, Tain Junn ^a,c,f   Chuu, Jiunn Jye ^b  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^f CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; PROTEIN KINASE B; RESERPINE; ARSENIC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BEHAVIOR; CELL PROLIFERATION; CONTROLLED STUDY; DEPRESSION; ELEVATED PLUS MAZE TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPLORATORY BEHAVIOR; FORCED SWIM TEST; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MOUSE; MOUSE MODEL; NONHUMAN; OPEN FIELD TEST; PREFRONTAL CORTEX; SIGNAL TRANSDUCTION; TAIL SUSPENSION TEST; WESTERN BLOTTING; ANIMAL; ANIMAL BEHAVIOR; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; HUMAN; MENTAL STRESS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SWIMMING;

MUS;

ANIMALS; ANXIETY; ARSENIC; BEHAVIOR, ANIMAL; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; HUMANS; MICE; PREFRONTAL CORTEX; RECEPTOR, TRKB; STRESS, PSYCHOLOGICAL; SWIMMING;

EID: 84934970299     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/159015     Document Type: Article

References (51)

1. F. Faita, L. Cori, F. Bianchi, and M. G. Andreassi, "Arsenicinduced genotoxicity and genetic susceptibility to arsenicrelated pathologies," International Journal of Environmental Research and Public Health, vol. 10, no. 4, pp. 1527-1546, 2013.
2. W.-M.Dang, W.-J.Ma, S. Wang et al., "Investigation on mental health of residents living in a mineral area in Hubei province," Chinese Journal of Industrial Hygiene and Occupational Diseases, vol. 26, no. 8, pp. 457-460, 2008.
3. W. E. Morton and G. A. Caron, "Encephalopathy: An uncommon manifestation of workplace arsenic poisoning?" American Journal of Industrial Medicine, vol. 15, no. 1, pp. 1-5, 1989.
4. D. Sen and P. S. Biswas, "Arsenicosis: Is it a protective or predisposing factor for mental illness?" Iranian Journal of Psychiatry, vol. 7, no. 4, pp. 180-183, 2012.
5. C. C. Yen, T. J. Ho, C. C.Wu et al., "Inorganic arsenic causes cell apoptosis in mouse cerebrum through an oxidative stressregulated signaling pathway," Archives of Toxicology, vol. 85, no. 6, pp. 565-575, 2011.
6. A. N. Chaudhuri, S. Basu, S. Chattopadhyay, and S. DasGupta, "Effect of high arsenic content in drinking water on rat brain," Indian Journal of Biochemistry & Biophysics, vol. 36, no. 1, pp. 51-54, 1999.
7. F. Piao, N. Ma, Y. Hiraku et al., "Oxidative DNA damage in relation to neurotoxicity in the brain of mice exposed to arsenic at environmentally relevant levels," Journal of Occupational Health, vol. 47, no. 5, pp. 445-449, 2005.
8. N. Ma, M. Sasoh, S. Kawanishi, H. Sugiura, and F. Piao, "Protection effect of taurine on nitrosative stress in the mice brain with chronic exposure to arsenic," Journal of Biomedical Science, vol. 17, no. 1, article S7, 2010.
9. S. Zarazúa, R. Riós, J. M. Delgado, M. E. Santoyo, D. Ortiz-Pérez, and M. E. Jiménez-Capdeville, "Decreased arginine methylation and myelin alterations in arsenic exposed rats," NeuroToxicology, vol. 31, no. 1, pp. 94-100, 2010.
10. F. Piao, S. Li, Q. Li, J. Ye, and S. Liu, "Abnormal expression of 8-nitroguanine in the brain of mice exposed to arsenic subchronically," IndustrialHealth, vol. 49,no. 2, pp. 151-157, 2011.
11. D. J. Nutt and D. J. Stein, "Understanding the neurobiology of comorbidity in anxiety disorders," CNS Spectrums, vol. 11, no. 12, pp. 13-20, 2006.
12. P. Boyer, "Do anxiety and depression have a common pathophysiological mechanism?" Acta Psychiatrica Scandinavica, Supplement, vol. 102, no. 406, pp. 24-29, 2000.
13. P. R. Albert,C. Benkelfat, and L. Descarries, "The neurobiology of depression-revisiting the serotonin hypothesis. I. Cellular and molecular mechanisms," Philosophical Transactions of the Royal Society B: Biological Sciences, vol. 367, no. 1601, pp. 2378-2381, 2012.
14. E. Molina, J. Cervilla, M. Rivera et al., "Polymorphic variation at the serotonin 1-A receptor gene is associated with comorbid depression and generalized anxiety," PsychiatricGenetics, vol. 21, no. 4, pp. 195-201, 2011.
15. J. P. Herman, N. K. Mueller, H. Figueiredo, and W. Cullinan, "Neurocircuit regulation of the hypothalamo-pituitaryadrenocortical stress response-an overview," in Handbook of Stress and the Brain, T. Steckler, N. Kalin, and J. M. Reul, Eds., pp. 405-418, Elsevier, London, UK, 2005.
16. M. J. Millan, S. Veiga, S. Girardon, and M. Brocco, "Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: A comparison to other 5-HT receptor subtypes," Psychopharmacology, vol. 168, no. 4, pp. 397-409, 2003.
17. R. S. Duman and B. Voleti, "Signaling pathways underlying the pathophysiology and treatment of depression: Novel mechanisms for rapid-acting agents," Trends in Neurosciences, vol. 35, no. 1, pp. 47-56, 2012.
18. J. M. Koch, D.Hinze-Selch, K. Stingele et al., "Changes in CREB Phosphorylation and BDNF plasma levels during psychotherapy of depression," Psychotherapy and Psychosomatics, vol. 78, no. 3, pp. 187-192, 2009.
19. S. Alboni, F. Tascedda, D. Corsini et al., "Stress induces altered CRE/CREB pathway activity and BDNF expression in the hippocampus of glucocorticoid receptor-impaired mice," Neuropharmacology, vol. 60, no. 7-8, pp. 1337-1346, 2011.
20. F.L.Neto,G. Borges,S.Torres-Sanchez, J.A.Mico, andE. Berrocoso, "Neurotrophins role in depression neurobiology: A review of basic and clinical evidence," CurrentNeuropharmacology, vol. 9, no. 4, pp. 530-552, 2011.
21. B. L. Jacobs, H. Van Praag, and F. H. Gage, "Adult brain neurogenesis and psychiatry: A novel theory of depression," Molecular Psychiatry, vol. 5, no. 3, pp. 262-269, 2000.
22. W. C. Drevets, "Neuroimaging and neuropathological studies of depression: Implications for the cognitive-emotional features of mood disorders," Current Opinion in Neurobiology, vol. 11, no. 2, pp. 240-249, 2001.
23. S. Liu, F. Piao, X. Sun et al., "Arsenic-induced inhibition of hippocampal neurogenesis and its reversibility," NeuroToxicology, vol. 33, no. 5, pp. 1033-1039, 2012.
24. J.-H. Luo, Z.-Q. Qiu, L. Zhang, andW.-Q. Shu, "Arsenite exposure altered the expression ofNMDA receptor and postsynaptic signaling proteins in rat hippocampus," Toxicology Letters, vol. 211, no. 1, pp. 39-44, 2012.
25. M. Q. Fan, Z. Zhi-Qu, and Z. Ping, "Effects of arsenic on nerve growth factor and nerve growth relatedmRNA expression in F1 hippocampal," Journal of Sichuan University, vol. 44, no. 1, pp. 53-56, 2013.
26. F. Tang, "Effect of reserpine on catecholamine contents and met-enkephalin and β-endorphin levels in the hypothalamus and the pituitary," Clinical and Experimental Pharmacology & Physiology, vol. 18, no. 6, pp. 425-429, 1991.
27. S. Iritani, M. Tohgi, T. Arai, and K. Ikeda, "Immunohistochemical study of the serotonergic neuronal system in an animal model of the mood disorder," Experimental Neurology, vol. 201, no. 1, pp. 60-65, 2006.
28. M. Komada, K. Takao, and T. Miyakawa, "Elevated plus maze for mice," Journal of Visualized Experiments, no. 22, article 1088, 2008.
29. L. Prut and C. Belzung, "The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: A review," European Journal of Pharmacology, vol. 463, no. 1-3, pp. 3-33, 2003.
30. L. Steru, R. Chermat, B. Thierry, and P. Simon, "The tail suspension test: A new method for screening antidepressants in mice," Psychopharmacology, vol. 85, no. 3, pp. 367-370, 1985.
31. K. Yamaura, N. Nakayama, M. Shimada, Y. Bi, H. Fukata, and K. Ueno, "Antidepressant-like effects of young green barley leaf (Hordeum vulgare L.) in the mouse forced swimming test," Pharmacognosy Research, vol. 4, no. 1, pp. 22-26, 2012.
32. G. D. Hilton, B. A. Stoica, K. R. Byrnes, and A. I. Faden, "Roscovitine reduces neuronal loss, glial activation, and neurologic deficits after brain trauma," Journal of Cerebral Blood Flow and Metabolism, vol. 28, no. 11, pp. 1845-1859, 2008.
33. P. P. Simeonova, T. Hulderman, D. Harki, and M. I. Luster, "Arsenic exposure accelerates atherogenesis in apolipoprotein E?/? mice," Environmental Health Perspectives, vol. 111, no. 14, pp. 1744-1748, 2003.
34. V. P. Markowski, D. Currie, E. A. Reeve, D. Thompson, and J. P. Wise Sr., "Tissue-specific and dose-related accumulation of arsenic in mouse offspring following maternal consumption of arsenic-contaminated water," Basic & Clinical Pharmacology & Toxicology, vol. 108, no. 5, pp. 326-332, 2011.
35. M.Mittal and S. J. S. Flora, "Effects of individual and combined exposure to sodium arsenite and sodium fluoride on tissue oxidative stress, arsenic and fluoride levels in male mice," Chemico-Biological Interactions, vol. 162, no. 2, pp. 128-139, 2006.
36. D.Yang, C. Liang, Y. Jin, andD.Wang, "Effect of arsenic toxicity onmorphology and viability of enzyme in primary culture of rat hippocampal neurons," Journal of Hygiene Research, vol. 32, no. 4, pp. 309-312, 2003.
37. L. Toschi and R. Bravo, "Changes in cyclin/proliferating cell nuclear antigen distribution during DNA repair synthesis," Journal of Cell Biology, vol. 107, no. 5, pp. 1623-1628, 1988.
38. D. H.Overstreet, R. C. Commissaris, R. De La Garza II, S. E. File, D. J. Knapp, and L. S. Seiden, "Involvement of 5-HT1A receptors in animal tests of anxiety and depression: Evidence fromgenetic models," Stress, vol. 6, no. 2, pp. 101-110, 2003.
39. E. J.Martinez, B. L. Kolb,A. Bell, D. D. Savage, andA. M. Allan, "Moderate perinatal arsenic exposure alters neuroendocrine markers associated with depression and increases depressivelike behaviors in adult mouse offspring," NeuroToxicology, vol. 29, no. 4, pp. 647-655, 2008.
40. T. Itoh, Y. F. Zhang, S.Murai et al., "The effect of arsenic trioxide on brain monoamine metabolism and locomotor activity of mice," Toxicology Letters, vol. 54, no. 2-3, pp. 345-353, 1990.
41. V. M. Rodríguez, L. Carrizales, M. E. Jiménez-Capdeville, L. Dufour, and M. Giordano, "The effects of sodium arsenite exposure on behavioral parameters in the rat," Brain Research Bulletin, vol. 55, no. 2, pp. 301-308, 2001.
42. F.Maekawa, T. Tsuboi,M.Oya et al., "Effects of sodiumarsenite on neurite outgrowth and glutamateAMPAreceptor expression in mouse cortical neurons," NeuroToxicology, vol. 37, pp. 197-206, 2013.
43. S. S. Haider and M. S. Najar, "Arsenic induces oxidative stress, sphingolipidosis, depletes proteins and some antioxidants in various regions of rat brain," Kathmandu University Medical Journal, vol. 6, no. 1, pp. 60-69, 2008.
44. X. Liu, F. Piao, and Y. Li, "Protective effect of taurine on the decreased biogenic amine neurotransmitter levels in the brain of mice exposed to arsenic," Advances in ExperimentalMedicine and Biology, vol. 776, pp. 277-287, 2013.
45. V. Arora, A. Kuhad, V. Tiwari, and K. Chopra, "Curcumin ameliorates reserpine-induced pain-depression dyad: Behavioural, biochemical, neurochemical and molecular evidences," Psychoneuroendocrinology, vol. 36, no. 10, pp. 1570-1581, 2011.
46. S. A. Bisong, R. Brown, and E. E. Osim, "Comparative effects of Rauwolfia vomitoria and chlorpromazine on locomotor behaviour and anxiety in mice," Journal of Ethnopharmacology, vol. 132, no. 1, pp. 334-339, 2010.
47. R. E.Moo-Puc, J. Villanueva-Toledo, G. Arankowsky-Sandoval, F. Alvarez-Cervera, and J. L. Góngora-Alfaro, "Treatment with subthreshold doses of caffeine plus trihexyphenidyl fully restores locomotion and exploratory activity in reserpinized rats," Neuroscience Letters, vol. 367, no. 3, pp. 327-331, 2004.
48. S. Ducharme, M. D. Albaugh, J. J. Hudziak et al., "Anxious/depressed symptoms are linked to right ventromedial prefrontal cortical thicknessmaturation in healthy children and young adults," Cerebral Cortex, vol. 24, pp. 2941-2950, 2014.
49. S. Rigucci, G. Serafini, M. Pompili, G. D. Kotzalidis, and R. Tatarelli, "Anatomical and functional correlates in major depressive disorder: The contribution of neuroimaging studies," World Journal of Biological Psychiatry, vol. 11, no. 2, part 2, pp. 165-180, 2010.
50. A. F. T. Arnsten, "Stress signalling pathways that impair prefrontal cortex structure and function," Nature Reviews Neuroscience, vol. 10, no. 6, pp. 410-422, 2009.
51. O.Valverde, T.Mantamadiotis, M. Torrecilla et al., "Modulation of anxiety-like behavior and morphine dependence in CREBdeficient mice," Neuropsychopharmacology, vol. 29, no. 6, pp. 1122-1133, 2004.